MiR-126: a novel route for natalizumab action?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Multiple Sclerosis

• Publication date

  2014-03-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/1352458514524998PMID 24598267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

  2013cited by this paper
• Dynamic regulatory network controlling Th17 cell differentiation

  2013cited by this paper
• Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment.

  2013cited by this paper
• MicroRNA dysregulation in multiple sclerosis

  2013cited by this paper
• Differential microRNA expression in blood in multiple sclerosis

  2013cited by this paper
• MicroRNAs in human cancer.

  2013cited by this paper
• Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

  2013cited by this paper
• Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.

  2012cited by this paper
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells

  2011cited by this paper
• Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis

  2011cited by this paper
• Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals

  2011cited by this paper
• Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity

  2010cited by this paper
• Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.

  2010cited by this paper
• Ets-1 and Ets-2 Regulate the Expression of MicroRNA-126 in Endothelial Cells

  2010cited by this paper
• Regulation of mRNA translation and stability by microRNAs.

  2010cited by this paper
• Altered expression of miR‐17‐5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients

  2010cited by this paper
• Differential Micro RNA Expression in PBMC from Multiple Sclerosis Patients

  2009cited by this paper
• microRNAs and the immune response

  2009cited by this paper
• MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis

  2009cited by this paper
• Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease

  2009cited by this paper
• Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.

  2008cited by this paper
• microRNAs and the immune response.

  2008cited by this paper
• Multiple sclerosis

  2008cited by this paper
• Natalizumab: A new treatment for relapsing remitting multiple sclerosis

  2007cited by this paper
• BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses

  2007cited by this paper
• Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

  2007cited by this paper
• Ets-1 is a negative regulator of Th17 differentiation

  2007cited by this paper
• The Ets factor Spi-B is a direct critical target of the coactivator OBF-1.

  2006cited by this paper
• Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans.

  2006cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper
• Multiple sclerosis.

  2002cited by this paper
• JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes.

  2000cited by this paper
• Personal correspondence

  1999cited by this paper
• Inducible expression and phosphorylation of coactivator BOB.1/OBF.1 in T cells.

  1997cited by this paper
• JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency

  1996cited by this paper
• The Ets protein Spi-B is expressed exclusively in B cells and T cells during development

  1996cited by this paper
• OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.

  1995cited by this paper

• MicroRNA biomarkers for JC virus reactivation and progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: a systematic review.

  2026cites this paper
• Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells

  2025cites this paper
• Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis

  2024cites this paper
• Women in the field of multiple sclerosis: How they contributed to paradigm shifts

  2023cites this paper
• The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistance.

  2023cites this paper
• MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate

  2023cites this paper
• Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma

  2023cites this paper
• Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders

  2022cites this paper
• MicroRNAs as a possible biomarker in the treatment of multiple sclerosis

  2022cites this paper
• Pharmacoepigenomics in neurodegenerative diseases

  2021cites this paper
• miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology

  2021cites this paper
• The role of microRNAs in multiple sclerosis

  2020cites this paper
• Epigenetics in Multiple Sclerosis.

  2020cites this paper
• Epigenetics in Allergy and Autoimmunity

  2020cites this paper
• Natalizumab related progressive multifocal leukoencephalopathy

  2020cites this paper
• Environmental Influencers, MicroRNA, and Multiple Sclerosis

  2020cites this paper
• microRNAs: key modulators of disease-modifying therapies in multiple sclerosis

  2020cites this paper
• MiR-145-5p: Its Roles in Oligodendrocyte Differentiation and Its Contributions to the Pathophysiology of Demyelinating Disease

  2020cites this paper
• Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs’ World

  2019cites this paper
• Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.

  2018cites this paper
• EGFL7 reduces CNS inflammation in mouse

  2018cites this paper
• Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients

  2018cites this paper
• Involvement of miR-126 in autoimmune disorders

  2018cites this paper
• Dysregulated Network of miRNAs Involved in the Pathogenesis of Multiple Sclerosis.

  2018cites this paper
• Dysregulated MicroRNA Involvement in Multiple Sclerosis by Induction of T Helper 17 Cell Differentiation

  2018cites this paper
• MicroRNA profiling of multiple sclerosis: from brain to blood

  2017cites this paper
• [MiRNAs: new actors in the physiopathology of multiple sclerosis].

  2017cites this paper
• A box of chocolates

  2016cites this paper
• Use of natalizumab in multiple sclerosis: current perspectives

  2016cites this paper
• miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients

  2016cites this paper
• Natalizumab-induced POU2AF1/Spi-B upregulation

  2016influential citation
• MicroRNAs associated with the pathogenesis of multiple sclerosis.

  2016cites this paper
• A link between long-term natalizumab dosing in MS and PML

  2016cites this paper
• Is It worth Considering Circulating microRNAs in Multiple Sclerosis?

  2016cites this paper
• PML risk stratification using anti-JCV antibody index and L-selectin

  2016cites this paper
• Epigenetics in multiple sclerosis

  2015cites this paper
• Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab

  2015cites this paper
• Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response

  2015cites this paper
• Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

  2015cites this paper
• Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

  2015cites this paper
• Animal Models for Progressive Multifocal Leukoencephalopathy

  2015cites this paper
• Mini Review Article

  year unknowncites this paper
• Natalizumab-induced POU 2 AF 1 / Spi-B upregulation A possible route for PML development

  year unknowninfluential citation